A glucocorticoid–FAS axis controls immune evasion during metastatic seeding

Steven

A glucocorticoid–FAS axis controls immune evasion during metastatic seeding

Summary

This Nature paper shows that activation of the glucocorticoid receptor (GR) in disseminated tumour cells (DTCs) suppresses FAS-mediated cell death, enabling DTCs to evade cytotoxic lymphocytes during the earliest steps of metastatic seeding. Using multiple mouse breast-cancer models (4T1, E0771), human TNBC lines and patient datasets, the authors combine scRNA-seq, bulk RNA-seq, CUT&RUN and functional assays to demonstrate that a GR-driven transcriptional programme lowers FAS expression and reduces FAS-driven apoptosis. Blocking GR (genetically or pharmacologically with agents such as mifepristone) restores FAS expression, increases FasL in NK and CD8+ T cells in the niche, and reduces early metastatic survival. A clinical GR activity signature correlates with hidden lesions and recurrence in triple-negative breast cancer (TBCRC-030 cohort) and with poorer outcomes in ER-negative/TNBC patients. Mechanistically, GR binding modulates apoptotic regulators (including BID/BH3 pathway components), linking GR activity to suppression of FAS-induced intrinsic apoptosis.

Key Points

  • GR activation in tumour cells downregulates FAS and a FAS-driven apoptotic programme, helping DTCs avoid killing by NK cells and CD8+ T cells.
  • Genetic GR knockdown (shGR) or pharmacological GR blockade increases FAS levels in DTCs and raises FasL expression in cytotoxic lymphocytes, enhancing DTC clearance.
  • ChIP/CUT&RUN shows GR binds genomic regions linked to apoptosis and BCL-2 family loci, and BH3 profiling implicates BID-dependent intrinsic death as the execution route downstream of FAS.
  • Preclinical models: GR activation (e.g. dexamethasone-treated tumour cells) increases lung metastatic seeding across multiple tumour types; blocking GR reduces early metastatic foci.
  • Clinical relevance: a GR activity gene signature associates with recurrent/hidden lesions and worse outcomes in ER-negative/TNBC patient cohorts (including TBCRC-030 analyses and public datasets).
  • Therapeutic implication: GR antagonism (for example mifepristone) or interventions that restore FAS signalling could improve immune-mediated clearance of DTCs and potentially sensitize metastasis to immunotherapy.

Context and relevance

Metastatic relapse is the main cause of cancer mortality; understanding how solitary DTCs survive immune surveillance at the seed stage is vitally important. This study links systemic or local glucocorticoid signalling to a concrete immune-evasion mechanism (suppression of FAS) and ties that to clinical datasets in TNBC. The findings matter for clinicians and researchers because glucocorticoids are widely used in cancer care (for symptom control, anti-emesis and to manage toxicities) and might inadvertently protect DTCs. The work suggests actionable strategies (GR antagonists, preserving/restoring FAS pathways) to reduce early metastatic seeding and improve immunotherapy efficacy.

Why should I read this?

Want to know why some stray cancer cells dodge your immune system and go on to seed metastases? This paper nails down a neat, druggable trick: GR shuts off FAS, and that lets DTCs hide. If you care about metastasis biology, TNBC, or how steroids might affect outcomes, this is the study that saves you time by spelling out the mechanism and pointing to real-world therapy implications.

Author voice

Punchy take: a high-impact, mechanistically tight study that links a common hormonal pathway to immune escape at the very start of metastasis — clinically relevant, experimentally rigorous and pointing straight at potential interventions. Read the full paper if you work on metastasis, immunotherapy or steroid use in oncology.

Source

Source: https://www.nature.com/articles/s41586-026-10222-2

Article Date: 04 March 2026
Article URL: https://www.nature.com/articles/s41586-026-10222-2
Article Image: (not provided)